References
1. Бокерия Л.А., Ревишвили А.Ш., Дубровский И.А. Состояние электрокардиостимуляции в России в 2011 г. Вестник аритмологии. 2013; 73: 75-9. / Bockeria L.A., Revishvili A.Sh., Dubrovskiy I.A. Status of pasing in Russia in 2001. Vestnik aritmologii. 2013; 73: 75-9 (in Russian).
2. Arribas F., Auricchio A., Wolpert C., Merkely B., Merino J.L., Boriani G. et ai. The EHRA White Book. Europace. 2012; 14: iii1-55.
3. Mond H.G., Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 - a World Society of Arrhythmia's project. Pacing Clin. Electrophysiol. 2011; 34: 1013-27.
4. Dubner S., Auricchio A., Steinberg J.S., Vardas P, Stone P, Brugada J. et al. 1SHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (ClEDs). Europace. 2012; 14: 278-93.
5. Bongiorni M.G., Di Cori A., Soldati E., Zucchelli G., Segreti L., Solarino G. et al. Iatrogenic risk of permanent pacemaker and defibrillator implantation. G. Ital. Cardiol. 2009; 10: 395-406.
6. Nielsen J.C., ThomsenP.E., HojbergS, MollerM., Vesterlund T., Dalsgaard D. et al. DANPACE Investigators. A comparison of single-lead atrial pacing with dualchamber pacing in sick sinus syndrome. Eur. Heart J. 2011; 32: 686-96.
7. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R. et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 2005; 352: 225-37.
8. Bogale N., Witte K., Priori S., Cleland J., Auricchio A., Gadler F. et al. Scientific Committee, National Coordinators and the Investigators. The European cardiac resynchronization therapy survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur. J. Heart Fail. 2011; 13: 974-83.
9. Бокерия Л.А., Филатов А.Г., Тарашвили Э.Г. Антикоагулянтная терапия у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2011; 3: 26-30. / Bockeria L.A., Filatov A.G., Tarashvili E.G. Anticoagulant therapy in patients with atrial fibrillation. Annaly aritmologii. 2011; 3: 26-30 (in Russian).
10. Nieuwlaat R., Prins M.H., Le Heuzey J.Y., Vardas P.E., AliotE., Santini M. et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur. Heart J. 2008; 29: 1181-9.
11. Moschovitis A., Cook S., Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention. 2010; 6: 189-94.
12. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6-e245.
13. Рычков А.Ю. Антикоагулянты при фибрилляции предсердий. Вестник аритмологии. 2008; 50: 46-9. / Rych- kov A.Yu. Anticoagulants in atrial fibrillation. Annaly arit- mologii. 2008; 50: 46-9 (in Russian).
14. Daubert J.C., Saxon L., Adamson P.B., Auricchio A., Berger R.D., Beshai J.F. et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012; 14: 1236-86.
15. Brignole M., Auricchio A., Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O.A. et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013; 15: 1070-118.
16. Lip G.Y., Proclemer A., Dagres N., Bongiorni M.G., Lewal- ter T., Blomstrom-Lundqvist C. Scientific Initiative Committee, European Heart Rhythm Association. Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace. 2012; 14: 741-4.
17. Douketis J.D., Spyropoulos A.C., Spencer F.A., Mayr M., Jaffer A.K., Eckman M.H. et al. American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e326S-50S.
18. Wiegand U.K., LeJeune D., Boguschewski F., BonnemeierH., Eberhardt F., Schunkert H. et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest. 2004; 126: 1177-86.
19. Reynolds M.R., Cohen D.J., Kugelmass A.D., Brown P.P., Becker E.R., Culler S.D. et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J. Am. Coll. Cardiol. 2006; 47: 2493-7.
20. Mahapatra S., Bybee K.A., Bunch T.J., Espinosa R.E., Sinak L.J., McGoon M.D. et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm. 2005; 2: 907-11.
21. Korantzopoulos P., Letsas K.P., Liu T., Fragakis N., Efremidis M., Goudevenos J.A. Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices. Europace. 2011; 13: 1669-80.
22. Birnie D.H., Healey J.S., Wells G.A., Verma A., Tang A.S., Krahn A.D. et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N. Engl. J. Med. 2013; 368: 2084-93.
23. Poole J.E., Gleva M.J, Mela T, Chung M.K., Uslan DZ, Borge R. et al. REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter- defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010; 122: 1553-61.
24. Lekkerkerker J.C., van Nieuwkoop C., Trines S.A., van der Bom J.G., Bernards A., van de Velde E.T. et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart. 2009; 95: 715-20.
25. Cano O., Osca J., Sancho-Tello M.J., Olague J., Castro J.E., Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace. 2011; 13: 395-401.
26. Michaud G.F., Pelosi F. Jr, Noble M.D., Knight B.P., Morady F., StrickbergerS.A. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J. Am. Coll. Cardiol. 2000; 35: 1915-8.
27. Zaca V., Marcucci R., Parodi G. et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015; 17(6): 840-54.
28. Uslan D.Z., Gleva M.J, Warren D.K., Mela T., Chung M.K., Gottipaty V. et al. Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE registry. Pacing Clin. Electrophysiol. 2012; 35: 81-7.
29. Lai C.H., Chen J.Y., Wu H.Y., Wen J.S., Yang Y.J. Successful conservative management with positive end-expiratory pressure for massive haemothorax complicating pacemaker implantation. Resuscitation. 2007; 75: 189-91.
30. Forleo G.B., Zeitani J., Perretta T., Della Rocca D.G., Santini L., Simonetti G. et al. Acute left hemothorax as a late complication of an active-fixation pacemaker lead. Ann. Thorac. Surg. 2013; 95: 1081-4.
31. Carlson M.D, Freedman R.A., Levine P.A. Lead perforation: incidence in registries. Pacing Clin. Electrophysiol. 2008; 31: 13-5.
32. Hirschl D.A., Jain V.R., Spindola-Franco H., Gross J.N., Haramati L.B. Prevalence and characterization of asymptomatic pacemaker and ICD lead perforation on CT. Pacing Clin. Electrophysiol. 2007; 30: 28-32.
33. Grubb B.P., Welch M., Kanjwal K., Karabin B, Kanjwal Y. An anatomic-based approach for the placement of implantable loop recorders. Pacing Clin. Electrophysiol. 2010; 33: 1149-52.
34. Bongiorni M.G., Soldati E., Zucchelli G, Di Cori A, Segreti L., De Lucia R. et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: high success rate and safety in more than 2000 leads. Eur. Heart J. 2008; 29: 2886-93.
35. Eisen G.M., Baron T.H., Dominitz J.A, Faigel D.O., Goldstein J.L., Johanson J.F. et al. American Society for Gastrointestinal Endoscopy. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest. Endosc. 2002; 55: 775-9.
36. Baron T.H., Kamath P.S., McBane R.D. Management of antithrombotic therapy in patients undergoing invasive procedures. N. Engl. J. Med. 2013; 368: 2113-24.
37. Schulman S., AngerAs U., Bergqvist D., Eriksson B., Lassen M.R., Fisher W. On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J. Thromb. Haemost. 2010; 8: 202-4.
38. Шубик Ю.В. Антитромботическая терапия при фибрилляции предсердий. Вестник аритмологии. 2014; 75: 50-75. / Shubik Yu.V. Antithrombotic therapy in atrial fibrillation. Vestnik aritmologii. 2014; 75: 50-75 (in Russian).
39. Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J. et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15: 625-51.
40. Biondi-Zoccai G.G., Lotrionte M., Agostoni P, Abbate A., Fusaro M., Burzotta F. et al. A systematic review and metaanalysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J. 2006; 27: 2667-74.
41. Oscarsson A., Gupta A., Fredrikson M., Jarhult J., Ny- strom M., Pettersson E. et al. To continue or discontinue aspirin in the peri-operative period: a randomized, controlled clinical trial. Br. J. Anaesth. 2010; 104: 305-12.
42. Maulaz A.B., Bezerra D.C., Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch. Neurol. 2005; 62: 1217-20.
43. Beving H., Zhao C., Albage A., Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul. Fibrinolysis. 1996; 7: 80-4.
44. Ho P.M., Peterson E.D., Wang L., Magid D.J., Fihn S.D., Larsen G.C. et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008; 299: 532-9.
45. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007; 297: 159-68.
46. lakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G. et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug eluting stents. JAMA. 2005; 293: 2126-30.
47. Spertus J.A, Kettelkamp R., Vance C., Decker C., Jones P.G, Rumsfeld J.S. et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug eluting stent placement: results from the PREMIER registry. Circulation. 2006; 113: 2803-9.
48. Rossini R., Capodanno D, Lettieri C., Musumeci G, Nija- radze T., Romano M. et al. Prevalence, predictors, and longterm prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am. J. Cardiol. 2011; 107: 186-94.
49. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D’Agostino R., Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 2007; 356: 1020-9.
50. Roy P., Bonello L., Torguson R., Okabe T., Pinto Slottow T.L., Steinberg D.H. et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am. J. Cardiol. 2009; 103: 801-5.
51. Airoldi F., Colombo A., Morici N., Latib A., Cosgrave J., Buellesfeld L. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopy- ridine treatment. Circulation. 2007; 116: 745-54.
52. Schulz S., Schuster T., Mehilli J., Byrne R.A., Ellert J., Massberg S. et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J. 2009; 30: 2714-21.
53. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H. et al. Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119: 987-95.
54. Eisenberg M.J., Richard P.R., Libersan D., Filion K.B. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009; 119: 1634-42.
55. Sarno G, Lagerqvist B, Frobert O., Nilsson J., Olivecrona G., Omerovic E. et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur. Heart J. 2012; 33: 606-13.
56. Park K.W., Kang S.H., Velders M.A., Shin D.H, Hahn S, Lim W.H. et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am. Heart J. 2013; 165: 241-50.
57. Palmerini T., Biondi-Zoccai G., Della Riva D., Stettler C., Sangiorgi D, D’Ascenzo F. et al. Stent thrombosis with drugeluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012; 379: 1393-402.
58. Ferreira-Gonzalez I., Marsal J.R., Ribera A., Permanyer- Miralda G, Garcfa-Del Blanco B, Marti G. et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J. Am. Coll. Cardiol. 2012; 60: 1333-9.
59. Stone G.W., Rutledge D.R., Sudhir K. et al. Stent thrombosis and dual antiplatelet interruption. Insights from the X1ENCE V everolimus-eluting coronary stent system trials (abstract). Abstract Presented at Transcatheter Therapeutics, San Francisco, California, USA, 2011. San Francisco; 2011.
60. Kirtane A., Silber S., Neumann F.J. et al. Therapy use and stent thrombosis following percutaneous coronary intervention with the resolute zotarolimus-eluting stent. Abstract presented at ACC, San Francisco, California, USA, 2013. J. Am. Coll. Cardiol. 2013; 61: 10S.
61. Tompkins C., Cheng A, Dalal D., Brinker J.A., Leng C.T., Marine J.E. et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J. Am. Coll. Cardiol. 2010; 55: 2376-82.
62. Rossini R., Bramucci E., Castiglioni B, De Servi S., Lettieri C., Lettino M. et al. Societa' Italiana di Cardiologia Invasiva (G1SE); Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO).: [Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation]. G. Ital. Cardiol. (Rome). 2012; 13: 528-51.
63. Valgimigli M., Campo G., Monti M., Vranckx P, Percoco G., Tumscitz C. et al. Shortversus long-term duration of dualantiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125: 2015-26.
64. Windecker S., Kolh P, Alfonso F., Collet J.P, Cremer J., Falk V. et al. Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPC1). Eur. Heart J. 2014; 35:2541-619.
65. Rodes-Cabau J., Dauerman H.L., Cohen M.G., Mehran R., Small E.M., Smyth S.S. et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J. Am. Coll. Cardiol. 2013; 62: 2349-59.
66. Savonitto S, Urbano M., Caracciolo M., Barlocco F, Mariani G., Nichelatti M. et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase 11 study of “bridging” antiplatelet therapy with tirofiban during temporary with drawal of clopidogrel. Br. J. Anaesth. 2010; 104: 285-91.
67. Angiolillo D.J., Firstenberg M.S., Price M.J., Tummala P.E., Hutyra M., Welsby I.J. et al. BR1DGE 1nvestigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012; 307: 265-74.
68. Wiviott S.D., Trenk D., Frelinger A.L., O’Donoghue M., Neumann F.J., Michelson A.D. et al. PR1NC1PLE-T1M1 44 1nvestigators. Prasugrel compared with high loading and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation. 2007; 116: 2923-32.
69. Wiviott S.D., Braunwald E., McCabe C., Montalescot G., Ruzyllo W., Gottlieb S. et al. TR1TON-T1M1 38 1nvestigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007; 357: 2001-15.
70. Gurbel P.A., Bliden K.P., Butler K., Tantry U.S., Gesheff T., Wei C. et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120: 2577-85.
71. Wallentin L., Becker R.C., Budaj A., Cannon C.P, Emanuels- son H., Held C. et al. for the PLATO 1nvestigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009; 361: 1045-57.
72. Held C., Asenblad N., Bassand J.P., BeckerR.C., Cannon C.P, Claeys M.J. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J. Am. Col. Cardiol. 2011; 57: 672-84.
73. Hamm C.W., Bassand J.P, Agewall S., Bax J, Boersma E., Bueno H. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32: 2999-3054.
74. Wysokinski W.E., McBane R.D., Daniels P.R., Litin S.C., Hodge D.O., Dowling N.F. et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin. Proc. 2008; 83: 639-45. Antithrombotic therapy in EP device surgery page 13 of 15 downloaded from by guest on May 23, 2015.
75. Douketis J.D., Johnson J.A., Turpie A.G. Low-molecular weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. 2004; 164: 1319-26.
76. Siegal D., Yudin J., Kaatz S., Douketis J.D., Lim W., Spyropoulos A.C. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and metaanalysis of bleeding and thromboembolic rates. Circulation. 2012; 126: 1630-9.
77. Douketis J.D. Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. Thromb. Haemost. 2012; 108: 210-2.
78. Spyropoulos A.C. Pro: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. Thromb. Haemost. 2012; 108: 213-6.
79. Gorenek B, Blomstrom Lundqvist C., Brugada Terradellas J., Camm A.J., Hindricks G, Huber K. et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPC1 task force. Europace. 2014; 16: 1655-73.
80. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008; 133: 98S-160S.
81. Gadisseur A.P, van der Meer F.J, Adriaansen H.J., Fihn S.D, Rosendaal F.R. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br. J. Haematol. 2002; 117: 940-6.
82. Palareti G., Legnani C. Warfarin with drawai. Pharmacokinetic pharmacodynamic considerations. Clin. Pharmacokinet. 1996; 30: 300-13.
83. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumaroi. Clin. Pharmacokinet. 2005; 44: 1227-46.
84. Friedland S., Soetikno R. Colonoscopy with polypectomy in anticoaguiated patients. Gastrointest. Endosc. 2006; 64: 98-100.
85. Kovacs M.J., Kearon C., Rodger M., Anderson D.R., Turpie A.G., BatesS.M. et ai. Singiearm study of bridging therapy with iow-moiecuiar-weight heparin for patients at risk of arterial emboiism who require temporary interruption of warfarin. Circulation. 2004; 110: 1658-63.
86. Larson B.J., Zumberg M.S., Kitchens C.S. Afeasibiiity study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboemboiic risk. Chest. 2005; 127: 922-7.
87. Steib A., Barre J., Mertes M., Morel M.H., Nathan N., Ozier Y. et ai. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? J. Thromb. Haemost. 2010; 8: 499-503.
88. Pengo V., Cucchini U., Denas G., Erba N., Guazzaloca G., La Rosa L. et ai. Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized iow moiecuiar-weight heparin bridging regimen in outpatients on orai anticoaguiants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009; 119: 2920-7.
89. Feng L., Li Y, Li J., Yu B. Oral anticoaguiation continuation compared with heparin bridging therapy among high risk patients undergoing impiantation of cardiac rhythm devices. A meta-anaiysis. Thromb. Haemost. 2012; 108: 1124-31.
90. Ghanbari H., Feldman D, Schmidt M., Ottino J., Machado C., Akoum N. et ai. Cardiac resynchronization therapy device impiantation in patients with therapeutic internationai normai- ized ratios. Pacing Clin. Electrophysiol. 2010; 33: 400-6.
91. Tischenko A, Gula L.J., Yee R., Klein G.J., Skanes A.C., Krahn A.D. Implantation of cardiac rhythm devices without interruption of orai anticoaguiation compared with perioperative bridging with iow-moiecuiar weight heparin. Am. Heart J. 2009; 158: 252-6.
92. Tolosana J.M., Berne P, Mont L., Heras M., Berruezo A., Monteagudo J. et ai. Preparation for pacemaker or impiantabie cardiac defibriiiator impiants in patients with high risk of thromboemboiic events: orai anticoaguiation or bridging with intravenous heparin? A prospective randomized triai. Eur. Heart J. 2009; 30: 1880-4.
93. Ahmed I., Gertner E., Nelson W.B., House C.M., Dahiya R., Anderson C.P. et ai. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoaguiation therapy in patients undergoing pacemaker and defibriiiator impiantation. Heart Rhythm. 2010; 7: 745-9.
94. Li H.K., Chen F.C., Rea R.F., Asirvatham S.J., Powell B.D., Friedman P.A. et ai. No increase bleeding events with continuation of orai anticoaguiation therapy for patients undergoing cardiac device procedure. Pacing Clin. Electrophysiol. 2011; 34: 868-74.
95. Cano O., Munoz B., Tejada D., Osca J., Sancho-Tello M.J., Olague J. et ai. Evaluation of a new standardized protocol for the perioperative management of chronicaiiy anticoaguiated patients receiving impiantabie cardiac arrhythmia devices. Heart Rhythm. 2012; 9: 361-7.
96. Marquie C., De Geeter G, Klug D., Kouakam C., Brigadeau F., Jabourek O. et ai. Postoperative use of heparin increases morbidity of pacemaker implantation. Europace. 2006; 8: 283-7.
97. Ghanbari H., Saint Phard W., Al-Ameri H., Latchamsetty R., Jongnarngsin K., Crawford T. et ai. Meta-anaiysis of safety and efficacy of uninterrupted warfarin compared to heparin- based bridging therapy during impiantation of cardiac rhythm devices. Am. J. Cardiol. 2012; 110: 1482-8.
98. Cheng A., Nazarian S., Brinker J.A., Tompkins C., Spragg D.D., Leng C.T. et ai. Continuation of warfarin during pacemaker or impiantabie cardioverter-defibriiiator impianta- tion: a randomized ciinicai trial. Heart Rhythm. 2011; 8: 536-40.
99. YangX., WangZ., Zhang Y, Yin X., Hou Y. The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-anaiysis. Europace. 2015; DO1:10.1093/europace/euu369.
100. Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P. et ai. WOEST study investigators. Use of ciopidogrei with or without aspirin in patients taking oral anticoaguiant therapy and undergoing percutaneous coronary intervention: an open-iabei, randomised, controlled trial. Lancet. 2013; 381: 1107-15.
101. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et ai. Dabigatran versus warfarin in patients with atriai fibriiiation. N. Engl. J. Med. 2009; 361: 1139-51.
102. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M. et ai. Apixaban versus warfarin in patients with atriai fibriiiation. N. Engl. J. Med. 2011; 365: 981-92.
103. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et ai. ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvaivuiar atriai fibriiiation. N. Engl. J. Med. 2011; 365: 883-91.
104. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L. et ai. ENGAGE AF-T1M1 48 1nvestigators. Edoxaban versus warfarin in patients with atriai fibrillation. N. Engl. J. Med. 2013; 369: 2093-104.
105. Healey J.S., Eikelboom J., Douketis J., Wallentin L., Oldgren J., Yang S. et ai. RE-LY Investigators. Periprocedurai bieeding and thromboemboiic events with dabigatran compared with warfarin: resuits from the randomized evaiuation of long-term anticoaguiation therapy (RE-LY) randomized trial. Circulation. 2012; 126: 343-8.
106. Rowley C.P, Bernard M.L., Brabham W.W., Netzler P.C., Sidney D.S., Cuoco F. et ai. Safety of continuous anticoaguia- tion with dabigatran during impiantation of cardiac rhythm devices. Am. J. Cardiol. 2013; 111: 1165-8.
107. Kosiuk J., Koutalas E., Doering M., Sommer P, Rolf S., Breithardt O.A. et ai. Treatment with novel oral anticoagulants in a reai-worid cohort of patients undergoing cardiac rhythm device impiantation. Europace. 2014; 16: 1028-32.